Umifenovir - instructions for use, dose, side effects, contraindications

Specifically suppresses influenza A and B viruses, coronavirus associated with severe acute respiratory syndrome. By the mechanism of antiviral action refers to the inhibitors of fusion (fusion), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes. Has a moderate immunomodulatory effect. Inductor interferon, stimulates the humoral and cellular immune responses, the phagocytic function of macrophages, increases the body's resistance to viral infections. Reduces the incidence of complications associated with a viral infection, as well as exacerbations of chronic bacterial diseases.

Therapeutic efficacy in viral infections is manifested in a decrease in the severity of general intoxication and clinical phenomena, shortening the duration of the disease, reducing the risk of complications.

Pharmacokinetics:

The maximum concentration in blood plasma when taken in a dose of 50 mg is achieved after 1.2 hours, at a dose of 100 mg - after 1.5 hours.

Metabolised in the liver. Half-lifeis 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in an insignificant number of kidneys (0.12%). During the first day, 90% of the administered dose is withdrawn.

Indications:

Prevention and treatment in adults and children: influenza A and B, acute respiratory viral infection, severe acute respiratory syndrome (including those complicated by bronchitis, pneumonia); secondary immunodeficiency states; complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection.

Prevention of postoperative infectious complications and normalization of the immune status.

Complex therapy of acute intestinal infections of rotavirus etiology in children older than 3 years.

ICD-10

I.B00-B09.B00 Infections caused by the herpes simplex virus [herpes simplex]

X.J10-J18.J11.8 Influenza with other manifestations, the virus is not identified

X.J10-J18.J11.1 Influenza with other respiratory manifestations, the virus is not identified

X.J10-J18.J11.0 Influenza with pneumonia, virus not identified

X.J10-J18.J11 Influenza, virus not identified

X.J10-J18 Influenza and pneumonia

X.J40-J47.J42 Chronic bronchitis, unspecified

X.J40-J47.J40 Bronchitis, not specified as acute or chronic

Contraindications:

Hypersensitivity, age to 3 years.

Carefully:

Children and the elderly, liver and kidney disease, pregnancy and lactation.

Pregnancy and lactation:

The category of FDA recommendations is not defined.

Adequate and well-controlled studies in humans and animals have not been conducted. There is no information on the penetration into breast milk. Use with caution.

Dosing and Administration:

Inside before meals.

Single dose: for children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years of age and adults - 200 mg (2 capsules or 100 mg tablets or 4 capsules or 50 mg tablets).

Nonspecific prevention.

In direct contact with patients with influenza and other SARS: children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years of age and adults - 200 mg once a day for 10-14 days.

During the epidemic of influenza and other acute respiratory infections, to prevent exacerbations of chronic bronchitis, recurrence of herpetic infection: children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years of age and adults - 200 mg twice a week for 3 weeks.

For prevention severe acute respiratory syndrome (when in contact with a patient): children from 6 to 12 years of age, 100 mg once a day; adults and children over 12 years of age are prescribed 200 mg once a day for 12-14 days.

Prevention of postoperative complications: children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years of age and adults - 200 mg for 2 days before the operation, then on the 2nd and 5th days after the operation.

Treatment.

Flu, other SARS without complications: children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years of age and adults - 200 mg 4 times a day (every 6 hours) for 5 days.

Influenza, other acute respiratory infections with complications (including bronchitis, pneumonia): children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years of age and adults - 200 mg 4 times a day (every 6 hours) for 5 days, then a single dose once a week for 4 weeks.

Severe acute respiratory syndrome: children over 12 years and adults - 200 mg 2 times a day for 8-10 days.

In the complex treatment of chronic bronchitis, herpes infection: children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years of age and adults - 200 mg 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.

Complex therapy of acute intestinal infections of rotavirus etiology in children older than 3 years: from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years - 200 mg 4 times a day (every 6 hours) for 5 days.

Side effects:

Allergic reactions: rarely.

Overdose:

Not described.

Interaction:

Not described.

Special instructions:

Refers to low-toxic compounds (LD50> 4 g / kg). Does not have any negative effects on the human body when administered orally at recommended doses.

It does not show central neurotropic activity and can be used in medical practice for preventive purposes in practically healthy persons of various professions, including requiring increased attention and coordination of movements (transport drivers, operators and others).

Instructions

Umifenovir (Umifenovirum)